Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

New data shows South County Fire’s cardiac arrest survival rate 1 is 71%, nearly double the national average. “Firefighters are very deliberately focused on providing the absolute best CPR for your ...

United States Pancreatic neuroendocrine tumors (PNETs) are rare tumors that are often diagnosed at advanced or metastatic stages, resulting in a poor prognosis. Sunitinib is an approved therapy for ...

A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant ... was found to improve overall survival and progression of the disease when matched with a chemotherapy ...

A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...

The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced ...